Novel circulating biomarkers for non-alcoholic fatty liver disease: A systematic review

Amirhossein Sahebkar, Elena Sancho, David Abelló, Jordi Camps, Jorge Joven

    Research output: Contribution to journalReview articlepeer-review

    15 Citations (Scopus)


    Currently, a liver biopsy remains the only reliable way to precisely diagnose non-alcoholic fatty liver disease (NAFLD) and establish the severity of liver injury, presence of fibrosis, and architecture remodeling. However, the cost and the intrinsic invasive procedure of a liver biopsy rules it out as a gold standard diagnostic test, and the imaging test are not the best choice due to the price, and currently is being refined. The lack of a biomarker of NAFLD pushes to develop this new line of research. The aim of the present systematic review is to clarify and update all the NAFLD biomarkers described in the literature until recently. We highlight α-ketoglutarate and CK18-F as currently the best potential biomarker of NAFLD. However, due to methodological differences, we propose the implementation of international, multicenter, multiethnic studies with larger population size, and biopsy proven NAFLD diagnosis to analyze and compare α-ketoglutarate and CK18-F as potential biomarkers of the silent evolution of NAFLD.

    Original languageEnglish
    Pages (from-to)849-855
    Number of pages7
    JournalJournal of Cellular Physiology
    Issue number2
    Publication statusPublished - 1 Feb 2018


    Dive into the research topics of 'Novel circulating biomarkers for non-alcoholic fatty liver disease: A systematic review'. Together they form a unique fingerprint.

    Cite this